PROGRAM CHAIRS
Ann H. Partridge, MD, MPH
Vice Chair of Medical Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio, MD Anderson Cancer Center
San Antonio, Texas
Abby Ciampa, MSN, APRN-BC
Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts
PROGRAM OVERVIEW
These podcasts provide expert perspectives on the role of gonadotropin-releasing hormone (GnRH) agonists for the treatment of early-stage breast cancer, as well as their role and that of ovarian function suppression (OFS) overall as an option for fertility preservation in premenopausal patients with breast cancer. By discussing real-world patient cases, experts also review some of the key evidence, as well as share important pearls on shared decision-making to optimize the utility and application of GnRH and OFS in these settings.
TARGET AUDIENCE
This activity is designed to educate medical oncologists, community oncologists, gynecologic oncologists, nurse practitioners (NPs), and physician assistants (PAs) who care for patients with early-stage breast cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Incorporate ovarian suppression using GnRH agonists into the treatment of early-stage breast cancer according to clinical trial data of optimal timing and duration and clinical practice guidelines.
- Evaluate the latest data of the ovarian preservation function of GnRH agonists among younger patients with early-stage breast cancer receiving chemotherapy
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of .50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of .50 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Ann H. Partridge, MD, MPH | Has received Wolters Kluwer Royalties for Authorship; has received research funding from Novartis. |
| Virginia Kaklamani, MD, DSc | Has received consulting fees from Puma, AstraZeneca, Gilead, TerSera, Daiichi, Lilly, Menarini; has served on speakers’ bureau for Pfizer, Gilead, Genentech, Novartis, AstraZeneca, Daiichi, Seagen; has received research funding from Eisai. |
| Abby Ciampa, MSN, APRN-BC | Has no relevant financial relationships |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Shannon Mutch, MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Andi Koral, Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation & Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: August 02, 2024
EXPIRATION DATE: August 02, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIRS
Ann H. Partridge, MD, MPH
Vice Chair of Medical Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio, MD Anderson Cancer Center
San Antonio, Texas
Abby Ciampa, MSN, APRN-BC
Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts
PROGRAM OVERVIEW
These podcasts provide expert perspectives on the role of gonadotropin-releasing hormone (GnRH) agonists for the treatment of early-stage breast cancer, as well as their role and that of ovarian function suppression (OFS) overall as an option for fertility preservation in premenopausal patients with breast cancer. By discussing real-world patient cases, experts also review some of the key evidence, as well as share important pearls on shared decision-making to optimize the utility and application of GnRH and OFS in these settings.
TARGET AUDIENCE
This activity is designed to educate medical oncologists, community oncologists, gynecologic oncologists, nurse practitioners (NPs), and physician assistants (PAs) who care for patients with early-stage breast cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Incorporate ovarian suppression using GnRH agonists into the treatment of early-stage breast cancer according to clinical trial data of optimal timing and duration and clinical practice guidelines.
- Evaluate the latest data of the ovarian preservation function of GnRH agonists among younger patients with early-stage breast cancer receiving chemotherapy
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of .50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of .50 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Ann H. Partridge, MD, MPH | Has received Wolters Kluwer Royalties for Authorship; has received research funding from Novartis. |
| Virginia Kaklamani, MD, DSc | Has received consulting fees from Puma, AstraZeneca, Gilead, TerSera, Daiichi, Lilly, Menarini; has served on speakers’ bureau for Pfizer, Gilead, Genentech, Novartis, AstraZeneca, Daiichi, Seagen; has received research funding from Eisai. |
| Abby Ciampa, MSN, APRN-BC | Has no relevant financial relationships |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Shannon Mutch, MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Andi Koral, Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation & Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: August 02, 2024
EXPIRATION DATE: August 02, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
